The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2014 ACR/ARHP Annual Meeting: Psoriatic Arthritis

2014 ACR/ARHP Annual Meeting: Psoriatic Arthritis

February 1, 2015 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

BOSTON—The pathogenesis of psoriatic arthritis, its clinical manifestations and ways to diagnosis it, along with a rational approach to treatment, were all discussed during a session on Psoriatic Arthritis: Skin, Entheses and Joints at the ACR/ARHP Annual Meeting in Boston in November 2014.

You Might Also Like
  • 2014 ACR/ARHP Annual Meeting: Fibrotic Complications of Scleroderma
  • 2014 ACR/ARHP Annual Meeting: Lung Fibrosis
  • 2013 ACR/ARHP Annual Meeting: Genetic Research Yields Clues to Pathogenesis of Rheumatoid Arthritis, Psoriatic Arthritis
Explore This Issue
February 2015
Also By This Author
  • Atacicept Shows Promise in Lupus Treatment Trials

Aim Higher: Treatment for Psoriasis

Kenneth B. Gordon, MD, professor of dermatology, Northwestern University, Feinberg School of Medicine, Chicago, opened the session with a discussion of current efforts to treat and improve treatment for psoriasis. Opening with a quote from John Updike, who described the humiliation of having psoriasis, Dr. Gordon emphasized the significant impact of this condition on patients’ lives in determining the goals of therapy.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

For example, he said that people with psoriasis on both their hands are considered to have a mild case of psoriasis, but he emphasized the significant impact this can have on, for example, professional people who, by etiquette, need to shake hands with their clients. He cited young women with scalp psoriasis as another example of patients who are significantly affected by the disease.

Citing data showing that the No. 1 reason that patients no longer seek treatment for psoriasis is that they’ve given up trying to get sufficient treatment, he highlighted that the goals of treatment often differ between patient and physician and urged physicians to think of psoriasis in the context of the general health of patients. This includes not only improving the primary disease, but also looking at and treating co-morbid diseases (such as frequent depression and cardiovascular disease) and overall emotional and economic needs that can significantly affect patients. For example, he said that the economic impact of psoriasis can be particularly significant for lower income people, a high percentage of whom have severe disease.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

As such, he recommends aggressive treatment for treating the skin disease (and not joint disease) in patients with psoriasis. Highlighting new information on the importance of achieving Psoriasis Area and Severity Index (PASI) of at least 90% reduction (PASI90) instead of the current standard measure of 75% reduction (PASI75) on improving the disease, he said that the PASI75 and PASI90 achieved with the current standard therapy with methotrexate is suboptimal.1,2

Other oral medications, such as apremilast, are similar to methotrexate in terms of PASI response, he said, but have a better tolerability that may be needed for some patients.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
Figure 1: Revised Treatment Strategy
click for large version
Figure 1: Revised Treatment Strategy

To provide more optimal treatment, he referred to new information on the pathogenesis of psoriasis that shows the importance of the IL-17 pathway in connecting the inflammatory response and clinical presentation of psoriasis.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Meeting Reports, Systemic Inflammatory Syndromes Tagged With: AC&R, Annual Meeting, Association of Rheumatology Professionals (ARP), Clinical, Diagnosis, Nierengarten, Psoriatic Arthritis, TreatmentIssue: February 2015

You Might Also Like:
  • 2014 ACR/ARHP Annual Meeting: Fibrotic Complications of Scleroderma
  • 2014 ACR/ARHP Annual Meeting: Lung Fibrosis
  • 2013 ACR/ARHP Annual Meeting: Genetic Research Yields Clues to Pathogenesis of Rheumatoid Arthritis, Psoriatic Arthritis
  • 2014 ACR/ARHP Annual Meeting: Lupus Nephritis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)